Use of Glucagon-like Peptide-1 Receptor Agonists May Lower Disease Activity and Slow Progression in Osteoarthritis and Inflammatory Arthritis

Obesity and related conditions may contribute to osteoarthritis through various biological mechanisms.

• Adipokine signaling, systemic inflammation, oxidative stress, and insulin resistance are factors linked to the development of osteoarthritis.
• Glucagon-like peptide-1 receptor agonists could provide musculoskeletal benefits beyond just promoting weight loss.
• Preclinical studies indicate potential anti-inflammatory, pain-relieving, and protective effects on cartilage from these treatments.
• Randomized trials in knee osteoarthritis show significant weight loss, with modest improvements in pain and function.
• Observational data suggest a possibility of cartilage preservation and lower rates of surgery, though findings are inconsistent.
• Current evidence regarding the effects in inflammatory arthritis remains promising but is still limited.

Simplified